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OBJECTIVES Our primary objective was to examine the prognostic relationship between baseline quanti-
tative ST-segment depression (ST2) and cardiac troponin T (cTnT) elevation. The
secondary objectives were to: 1) examine whether ST2 provided additional insight into
therapeutic efficacy of glycoprotein IIb/IIIa therapy similar to that demonstrated by cTnT;
and 2) explore whether the time to evaluation impacted on each marker’s relative prognostic
utility.
BACKGROUND The relationship between the baseline electrocardiogram (ECG) and cTnT measurements in
risk-stratifying patients presenting with acute coronary syndromes (ACS) has not been
evaluated comprehensively.
METHODS The study population consisted of 959 patients enrolled in the cTnT substudy of the Platelet
IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global
Organization Network (PARAGON)-B trial. Patients were classified as having no ST2 (n
 387), 1 mm ST2 (n  433), and ST2 2 mm (n  139). Forty-percent (n  381) were
classified as cTnT-positive based on a definition of 0.1 ng/ml.
RESULTS Six-month death/(re)myocardial infarction rates were 8.4% among cTnT-negative patients
with no ST2 and 26.8% among cTnT-positive patients with ST22 mm. On ECGs done
after 6 h of symptom onset, ST2 2 mm was associated with higher risk compared to its
presence on ECGs done earlier (odds ratio [OR] 7.3 vs. 2.1). In contrast, the presence of
elevated cTnT within 6 h of symptom was associated with a higher risk of adverse events
compared with elevations after 6 h (OR 2.4 vs. 1.5).
CONCLUSIONS Quantitative ST2 and cTnT status are complementary in assessing risk among ACS patients
and both should be employed to determine prognosis and assist in medical decision
making. (J Am Coll Cardiol 2003;41:371–80) © 2003 by the American College of
Cardiology Foundation
The introduction of cardiac troponin measurements into
routine clinical practice has been an important milestone in
the continuing quest for more effective early risk stratifica-
tion of patients presenting with acute coronary syndromes
(ACS). Higher cardiac troponin levels are associated with
worse outcomes in both ST-segment elevation myocardial
infarction (MI) (1) and non–ST-segment elevation ACS
patients (2,3). In addition to a prognostic role, elevated
levels of this biomarker appear to effectively identify patients
with an increased likelihood of intracoronary thrombi and
complex coronary lesions (4–6) which are most likely to
benefit from either antithrombin or intravenous glycopro-
tein (GP) IIb/IIIa inhibitor therapy (7–13).
Another diagnostic tool, the presenting 12-lead electro-
cardiogram (ECG), provides the earliest available objective
information for risk stratification of most ACS patients
(14 –17). Whereas the qualitative importance of ST-
segment depression (ST2) on the baseline ECG of ACS
patients is recognized clinically, quantification of this phe-
nomenon is rarely used in clinical practice. In a recent
evaluation of patients from the Platelet IIb/IIIa Antagonism
for the Reduction of Acute coronary syndrome events in a
Global Organization Network (PARAGON)-A study, we
documented the prognostic importance of quantitative
ST2 for one-year mortality among non–ST-segment ele-
vation ACS patients (18). Patients with ST2 of 2 mm in
two contiguous leads were approximately six times (odds
ratio [OR] 5.73; 95% confidence interval [CI]: 2.8, 11.6)
more likely to die within one year than patients with no with
ST2.
Because cardiac troponin T (cTnT) takes a finite time to
appear whereas the ECG is more immediately responsive to
an acute ischemic event, their potential complementary role
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in risk-stratifying patients presenting with ACS is of inter-
est. The relationship between these two fundamental diag-
nostic tests assessed quantitatively in a core laboratory has
not been evaluated comprehensively and is the primary
objective of the current study. The secondary objectives of
the study were to: 1) examine whether quantitative ST2
provided additional insight into therapeutic efficacy of GP
IIb/IIIa therapy similar to that demonstrated by cTnT; and
2) explore whether the time to evaluation (i.e., time between
symptom onset and ECG or to when cTnT was drawn) had
an impact on each marker’s relative prognostic utility.
METHODS
Patient population. The study population consisted of
patients enrolled in the troponin T substudy of the
PARAGON-B trial. Both the overall PARAGON-B study
and the troponin substudy have been described earlier
(7,19). Briefly, the PARAGON-B study enrolled 5,225
patients 21 years of age with non–ST-segment elevation
ACS who presented within 12 h of symptom onset and who
had symptoms lasting 10 min. All patients had evidence
of cardiac ischemia, based on either ECG changes or
elevated creatine kinase-MB or troponin T or I by local
laboratory standards. Patients were randomized in a blinded
fashion to either lamifiban or placebo therapy. The primary
end point was the composite of death, MI, or severe,
recurrent ischemia at 30 days. Six-month death and (re)MI
were assessed as secondary end points. The institutional
review board approved the substudy protocol at each site.
Cardiac troponin measurement. Of the 5,225 PARAGON-
B patients, 1,160 patients were prospectively enrolled in the
troponin T substudy. All cTnT measurements were per-
formed with the third-generation troponin T STAT elec-
trochemiluminescent immunoassay on the Elecsys 2010
system (Roche Diagnostics Corporation, Indianapolis, Indi-
ana) at a Clinical Laboratory Improvement Act-accredited
core lab at the Department of Pathology, University of Mary-
land School of Medicine. The minimum detectable concen-
tration was 0.01 ng/ml, and the imprecision (coefficient of
variation [CV]) observed at the core lab was 6.2% at both 0.15
and 6.0 ng/ml concentrations, consistent with the specifica-
tions of the manufacturer of a 6.0% CV at 5.07 ng/ml and
9.3% CV at 0.10 ng/ml for this U.S. Food and Drug
Administration cleared assay. Imprecision (CV) at low tropo-
nin T concentrations was validated as 10% at a concentration
of 0.03 ng/ml by the core lab. These data are consistent with
the imprecision specified in the manufacturer’s insert of 6% at
0.09 ng/ml, 7% at 0.06 ng/ml, 10% at 0.03 ng/ml, and 30% at
0.01 ng/ml. Patients with cTnT levels 0.1 ng/ml were
categorized as cTnT-positive. Thirty-day and six-month end
points were used as determined for the main PARAGON-B
study (7). Baseline ECG data were available for 1,112 (96%)
cTnT substudy patients.
ECG parameters. All ECG data were evaluated centrally
at the ECG core laboratory at the University of Alberta.
The ECGs were recorded in 12-lead format at a paper
speed of 25 mm/s. The ST2 was judged to be present if the
J point was depressed by 1 mm or more and was followed by
a horizontal or downward sloping ST-segment for at least
0.08 s in one or more of the 12 leads except aVR.
For purposes of our analysis, ST2 was categorized into
three mutually exclusive groups: no ST2, 1 mm ST2 in
two contiguous leads, and ST2 2 mm in two contiguous
leads. Patients with potentially confounding factors affect-
ing ECG interpretation, including left bundle branch block,
right bundle branch block, left ventricular hypertrophy,
ventricular pacemakers, or with incomplete ECG were
excluded from the analysis.
Outcomes. The relationships between baseline ST-
segment status and cTnT positivity and both short- and
long-term outcomes, namely 30-day and 6-month (re)MI
after admission and/or death, were examined. Six-month
follow-up status was available for 97% of the patients
enrolled in the PARAGON-B troponin T substudy.
Treatment effect. In the troponin T substudy, lamifiban
was associated with a significant reduction in the 30-day
primary end point among cTnT-positive patients (from
19.4% to 11.0%; p  0.01) resulting in rates that were
comparable to those among cTnT-negative patients (11.2%
for placebo vs. 10.8% for lamifiban) (7). We examined
whether the therapeutic response to treatment among pa-
tients with positive troponin persisted at six months. The
relationship between the extent of ST2 and six-month
death/(re)MI by treatment assignment was also examined to
determine whether the marker provided additional insights
into the therapeutic efficacy of GP IIb/IIIa therapy.
Time effect. We conducted exploratory analyses to deter-
mine whether the time from symptom onset to ECG and to
when cTnT samples were drawn had an impact on the
prognostic significance of the markers. Patients were clas-
sified according to whether the ECG and cTnT were done
within 6 h of symptom onset or later. The relationship of
ST2 and troponin positivity to six-month death/(re)MI
outcomes were examined within each stratum. The 6-h
window was selected for consistency with earlier studies (3)
and because it has been suggested that cTnT drawn 6 to
Abbreviations and Acronyms
ACS  acute coronary syndromes
CI  confidence interval
CV  coefficient of variation
cTnT  cardiac troponin T
ECG  electrocardiogram
GP  glycoprotein
IQR  interquartile range
MI  myocardial infarction
OR  odds ratio
PARAGON  Platelet IIb/IIIa Antagonism for the
Reduction of Acute coronary syndrome
events in a Global Organization Network
trial
ST2  ST-segment depression
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12 h after symptom onset is optimum in risk stratification
(20).
Statistical analyses. Chi-square tests (for categorical vari-
ables) and the nonparametric Kruskal-Wallis tests (for
continuous variables) were used to compare characteristics
across groups of patients. Kaplan-Meier analysis was used to
study the relationship between the magnitude of ST2 and
cTnT positivity and six-month death/(re)MI rates. Survival
curves were compared using the log-rank test statistic.
The univariate associations between ST2 categories and
cTnT status and adverse outcomes were measured using
both chi-squared tests and logistic regression analysis.
Transformations of the continuous cTnT variable were
considered to better examine its relationship with long-term
outcomes.
A multivariable logistic regression model was developed
to assess the combined prognostic value of positive cTnT
and ST2 categories in predicting six-month death or
(re)MI. Univariate analyses of baseline variables were fol-
lowed by a backward stepwise variable selection procedure.
The magnitude of ST2 (0, 1, and 2 mm) was included as
a categorical variable. The cTnT variable was included as a
continuous variable, a dichotomous variable (with values
above 0.1 ng/ml being assigned a value of 1), as well as a
categorical variable (using quartiles as cut points). The
overall performance of the final model was assessed using
the c-index. The 95% CI around the estimate (i.e., the
interval within which we can say with 95% probability that
the true c-index value is contained) was also calculated.
The c-index is a measure of model discrimination: the
extent to which the model predicts higher probabilities of
outcome for patients who have the outcome and is equal
to the area under the receiver operating characteristic
curve (21).
RESULTS
Baseline ECG data were available for 1,112 (96%) of the
1,160 patients enrolled in the PARAGON-B troponin T
substudy (Fig. 1). There were no differences in baseline
characteristics or outcomes, other than a higher rate of
previous MI (46% vs. 31%; p  0.04) and prior coronary
artery bypass graft (19% vs. 10%; p  0.05), between the 48
patients with no ECG data and those with ECG data.
Among the 1,112 patients with ECG data, 153 (14%) had
ECG confounders and were excluded from the analyses.
Patients with ECG confounders were significantly older
and had higher frequency of risk factors such as prior heart
failure, hypertension, and diabetes. Six-month mortality/
(re)MI rate among patients with ECG confounders was
15% and 42% of these patients were classified as troponin
positive.
After excluding patients with ECG confounding factors,
the final study population consisted of 959 patients: 387
(40%) had no ST2; 433 (45%) had ST2 of 1 mm in two
contiguous leads; and 139 (15%) had ST2 of 2 mm in
two contiguous leads. Based on a definition of 0.1 ng/ml
used in the cTnT substudy, 381 (40%) were classified as
cTnT-positive.
Baseline characteristics of the patient population accord-
ing to ST2 categories are presented in Table 1. Patients
with ST2 2 mm were older, more likely male, and less
likely to have undergone prior percutaneous coronary inter-
vention. These patients had significantly higher rates of
hypertension, prior MI, prior angina, peripheral vascular
disease, and history of congestive heart failure. Extent of
ST2 and cTnT-positivity were positively correlated (Pear-
son correlation coefficient  0.17, p  0.01): patients with
ST2 2 mm had the highest median cTnT levels (0.15
ng/ml, interquartile range [IQR]: 0.02, 0.49) compared
Figure 1. Description of the patient population. ECG electrocardiogram; ST-dep ST-segment depression; TnT troponin; T troponin negative;
T  Troponin positive.
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with median values of 0.05 ng/ml (IQR: 0.0, 0.29) among
patients with ST2 of 1 mm and 0.03 ng/ml (IQR: 0.0,
0.21) among patients with no ST2 (p  0.01).
Prognostic significance of ST-segment depression on
baseline ECG. Adverse outcomes by ST2 categories are
presented in Table 2. At six months, the (re)MI rate among
patients with ST2 2 mm (16.7%) was almost twice that
of patients with no ST2 (8.6%). In addition, the mortality
rate among patients with ST2 2 mm was 10.1% com-
pared with 1.8% among patients with no ST2. Figure 2A
shows the Kaplan-Meier six-month death/(re)MI curves for
the three ST2 subgroups. Survival free of (re)MI among
patients with no ST2 was significantly higher compared
with those with ST2 of 1 mm (log-rank statistic  4.2; p
 0.04) and ST2 2 mm (log-rank statistic  14.2; p 
0.01). Similarly, the difference in survival between patients
with 1 mm ST2 was significantly higher than that of
patients with 2 mm ST2 (log-rank statistic  4.6; p 
0.03).
Prognostic significance of troponin measures. The cTnT
measurements ranged from 0.0 to 8.37 ng/ml in this
population. In Table 3 and Figure 2B we present adverse
outcomes by cTnT status using the PARAGON-B tropo-
nin T substudy definition of 0.1 ng/ml considered cTnT-
positive. Six-month (re)MI-free survival among cTnT-
positive patients was significantly lower than that of cTnT-
negative patients (log-rank statistic  10.24; p  0.01).
We further explored the relationship between continuous
Table 1. Baseline Characteristics of PARAGON-B Patients by ST2 Categories
Characteristics No ST2 ST2  1 mm ST 2 > 2 mm p Value
Sample size 387 433 139
Age* 61 (51, 68) 65 (55, 73) 69 (61, 74)  0.01
Female 35.1 42.0 28.8 0.01
Race (Caucasian) 89.1 95.4 95.7  0.01
Heart rate* 71 (61, 82) 76 (65, 87) 83 (74, 94)  0.01
Systolic BP* 135 (120, 152) 140 (124, 160) 140 (130, 165)  0.01
Diastolic BP* 80 (70, 90) 80 (76, 90) 85 (80, 92)  0.01
Family history of CHD 46.4 37.0 34.8  0.01
Prior heart failure 7.2 8.8 15.8 0.01
Hypertension 53.2 53.6 67.6  0.01
Hypercholesterolemia 44.2 45.4 46.8 0.86
Prior angina 65.4 66.5 79.9  0.01
Diabetes 17.6 20.8 23.0 0.30
Smoking  0.01
Never 35.4 42.5 40.3
Past 29.7 31.6 38.1
Current 34.4 25.9 21.6
Stroke 3.9 3.2 4.3 0.80
TIA 1.6 3.5 2.9 0.22
Previous MI 26.4 27.5 41.7  0.01
Prior angio 30.5 25.6 20.9 0.07
Prior PTCA 14.2 10.9 6.5 0.04
Prior CABG 10.1 9.5 5.8 0.31
Severe COPD 4.9 4.4 4.3 0.93
Cancer 3.6 2.1 1.4 0.25
CRF 0.8 0.9 2.9 0.12
PVD 5.4 7.6 12.9 0.02
Arrhythmias 9.6 11.1 17.3 0.05
Enroll MI 30.2 32.6 38.8 0.10
Troponin
Troponin 32.3 40.2 59.0  0.01
Troponin measure* 0.03 (0.0, 0.21) 0.05 (0.0, 0.29) 0.15 (0.02, 0.49)  0.01
*Values presented are medians and interquartile range.
BP  blood pressure; CABG  coronary artery bypass surgery; CHD  coronary heart disease; COPD  chronic
obstructive pulmonary disease; CRF  chronic renal failure; MI  myocardial infarction; PARAGON  platelet IIb/IIIa
Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network trial; PTCA 
percutaneous transluminal coronary angioplasty; PVD  peripheral vascular disease; ST2  ST-segment depression; TIA 
transient ischemic attack.
Table 2. Outcomes by ST2 category
Characteristics No ST2 ST2  1 mm ST2 > 2 mm
p
Value
Sample size 387 433 139
Death 48 h 0.0 0.5 1.4 0.08
Death 30 day 0.8 3.2 5.0  0.01
Death 6 month 1.8 6.1 10.1  0.01
MI 48 h 2.1 2.8 4.3 0.37
MI 30 day 8.0 11.6 14.4 0.07
MI 6 month 8.6 11.8 16.7 0.03
Death/MI 48 h 2.1 3.2 5.8 0.10
Death/MI 30 day 8.3 12.9 17.3 0.01
Death/MI 6 month 9.8 14.5 22.3 0.01
Abbreviations as in Table 1.
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cTnT values and long-term outcomes by considering several
transformations. Figure 3 shows six-month rates of death/
(re)MI by cTnT quartiles. The categorization of all patients
with no troponin elevation (0.0 ng/ml) in the first quartile
resulted in an unequal distribution of patients in the first
and second quartile. Overall, 365 patients with a cTnT level
of 0.0 ng/ml cTnT were categorized as the first quartile;
patients with cTnT levels between 0.01 and 0.047 ng/ml
were categorized as second (n  113); from 0.048 to 0.277
as third (n  241); and all cTnT levels 0.278 ng/ml were
included in the fourth quartile (n  240). Death/(re)MI
rates ranged from 6.3% in the first cTnT quartile to 20.8%
in the fourth quartile (chi-squared test for trend  30.6; p
 0.001). The biggest increment in adverse event rate was
seen between the first two quartiles (from 6.3% to 14.2%).
Prognostic significance of combining ECG and cTnT
data. Figure 4 shows the six-month death/(re)MI rates by
ST2 and cTnT status (positive 0.1 ng/ml). Rates ranged
from 8.4% among patients with no ST2 and negative
cTnT to 26.8% among patients with ST2 2 mm and
positive cTnT. Within each ST2 category positive cTnT
was associated with higher risk; however, these differences
did not reach statistical significance. The difference was
most pronounced among patients with ST2 2 mm
(15.8% among cTnT-negative vs. 26.8% among cTnT-
positive, p  0.15).
Table 4 shows the univariate and multivariable associa-
tion between baseline variables and six-month death/
(re)MI. Individually, both ST2 and cTnT (irrespective of
categorization) were significant predictors of adverse out-
comes (see univariate ORs column in Table 4). Odds ratios
associated with a unit change in cTnT are difficult to
interpret clinically and given our finding that quartiles were
a more sensitive marker of risk compared with the dichot-
omous cTnT variable, cTnT quartiles were used in the
multivariable analysis. After adjusting for other baseline
factors, both ST2 and cTnT remained prognostically
significant. Patients with ST2 2 mm were twice as likely
to experience an adverse outcome compared with patients
with no ST2 (OR 1.91; 95% CI: 1.10 to 3.32) while
patients with cTnT levels higher than 0.278 ng/ml had
approximately four times the likelihood of death or (re)MI
compared with patients with no cTnT elevation (OR 3.86;
95% CI: 2.24 to 6.66). Other significant predictors included
prior percutaneous coronary intervention, peripheral vascu-
lar disease, and increasing age. The c-statistic for the model
was 0.70 (95% CI: 0.65 to 0.75) indicating that the model
had a moderately good ability to discriminate between
patients who did and did not experience the outcome.
Treatment effect. Treatment effects according to ST2
and cTnT status are presented in Tables 5 and 6. In general,
patients treated with lamifiban had lower adverse event rates
compared to patients in the placebo arm across ST2
categories; however, these differences did not reach statisti-
cal significance. The significant reduction in (re)MI events
among cTnT-positive patients treated with lamifiban ob-
Figure 2. Kaplan-Meier curves of six-month survival free of death/(re)myocardial infarction. (A) Categorized by ST-segment depression categories. *Log
rank statistics (0 vs. 1 mm)  4.2 (p  0.04). #Log rank statistic (0 vs. 2 mm)  14.2 (p  0.01). **Log rank statistic (1 vs. 2 mm)  4.6 (p  0.03).
(B) Categorized by troponin status. *Log rank statistics  10.24 (p  0.01).
Table 3. Outcomes by Troponin Status
Characteristics Troponin Troponin p Value
Sample size 578 381
Death 48 h 0.2 0.8 0.31
Death 30 day 1.7 3.7 0.09
Death 6 month 3.3 7.4  0.01
MI 48 h 1.6 4.5  0.01
MI 30 day 9.0 12.9 0.07
MI 6 month 9.7 13.6 0.07
Death/MI 48 h 1.7 5.2  0.01
Death/MI 30 day 9.5 15.0 0.01
Death/MI 6 month 10.9 18.1  0.01
Abbreviations as in Table 1.
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Figure 3. Six-month death/(re)myocardial infarction (MI) rates by troponin quartiles.
Figure 4. Six-month death/(re)myocardial infarction (MI) rates by ST-segment depression categories and troponin status. Shaded square  troponin 
closed square  troponin .
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served at 30 days persisted at 6 months. However, as
documented in the main PARAGON-B troponin substudy
paper, there was no significant treatment difference in the
six-month composite death/(re)MI rates (7). Overall, treat-
ment with lamifiban did not have a significant impact on
six-month death/(re)MI rates either in the univariate or in
the multivariable context.
Time effect. Table 7 describes the impact of time to
evaluation on the relationship between the markers and
six-month death/(re)MI. The median time to ECG was
1.7 h (IQR: 0.2, 4.1) and the median time to cTnT was
6.8 h (IQR: 4.0, 10.2). The ECGs were done within 6 h of
symptom onset in 743 (78%) of patients enrolled in the
study and after 6 h in 144 (15%) patients. The frequency of
ST2 2 mm was lower in the latter group (8% vs. 16%; p
 0.02); however, its presence was associated with a far
greater risk of six-month death/(re)MI (OR of 7.3 com-
pared to 2.1).
With respect to cTnT, a majority of the patients (n  532,
56%) had their cTnT drawn after 6 h of symptom onset.
However, the presence of elevated cTnT (0.1 ng/ml) within
6 h of symptom onset was associated with higher risk of
adverse outcome than the presence of elevated cTnT after 6 h
(OR 2.4; 95% CI: 1.4, 4.2 vs. OR 1.5; 95% CI: 0.92, 2.5).
Table 4. Univariate and Multivariable Associations—Death/MI 6 Months
Variable
Univariate Associations Multivariable Associations*
OR Lower CI Upper CI OR Lower CI Upper CI
Age (10 yr increments) 1.25 1.16 1.36 1.15 1.05 1.26
Gender 0.92 0.63 1.35
Diastolic blood pressure 1.00 0.99 1.01
Systolic blood pressure 1.00 1.00 1.01
Heart rate 1.00 0.99 1.01
Hypertension 1.10 0.76 1.60
Diabetes 1.64 1.08 2.50
Hyperlipidemia 1.30 0.90 1.88
Family history of CHD 1.11 0.77 1.62
Previous MI 1.33 0.90 1.96
Previous angina 1.42 0.94 2.15
Prior PTCA 1.66 1.00 2.76 1.86 1.09 3.16
Prior CABG 1.21 0.66 2.21
Severe COPD 2.19 1.08 4.44
Cancer 1.20 0.41 3.55
Peripheral vascular disease 2.66 1.53 4.62 2.32 1.29 4.17
Congestive heart failure 1.50 0.89 2.53
Stroke/TIA 2.04 1.07 3.92
Smoking
Past 1.49 0.96 2.31
Current 1.31 0.83 2.08
ST-segment depression
1 mm 1.56 1.02 2.40 1.34 0.86 2.09
2 mm 2.64 1.57 4.44 1.91 1.10 3.32
Troponin†‡
0.01–0.047 ng/ml 2.45 1.25 4.82 2.43 1.22 4.85
0.048–0.277 ng/ml 3.23 1.89 5.16 3.18 1.83 5.53
0.278–8.37 ng/ml 3.91 2.32 6.61 3.86 2.24 6.66
*C-statistic  0.70, 95% CI  0.65 to 0.75; †cTnT as dichotomous value (0.1 ng/ml): univariate OR  1.81, 95% CI  1.25
to 2.62; multivariable OR  1.57 (1.06 to 2.33); ‡cTnt as a continuous value: univariate OR  1.31, 95% CI  1.06 to 1.61;
multivariable OR  1.23 (0.99 to 1.54).
CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.
Table 5. Treatment Effect by ST2 Status
Characteristics No ST2 ST2  1 mm ST2 > 2 mm
Treatment Rx Placebo Rx Placebo Rx Placebo
Sample size 190 197 226 207 64 75
Death 30 day 0.0 1.5 3.1 3.4 4.7 5.3
Death 6 month 1.1 2.6 6.7 5.4 9.5 10.7
MI 30 day 6.3 9.6 9.8 13.6 14.1 14.7
MI 6 month 6.5 10.7 10.4 13.3 15.9 17.3
Death/MI 30 day 6.3 10.2 11.5 14.5 17.2 17.3
Death/MI 6 month 7.4 12.2 13.7 15.5 21.9 22.7
Abbreviations as in Table 1.
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DISCUSSION
Our study documents the complementary role of baseline
quantitative ST2 and cTnT measurement in risk-
stratifying non–ST-segment elevation ACS patients. In
combination, the markers appear to provide an integrated
and improved delineation of the spectrum of ACS risk: with
the lowest rates of adverse outcomes being observed in
cTnT-negative patients with no ST2 (8.4%) and the
highest rates being observed in cTnT-positive patients with
ST2 2mm (26.8%). In a multivariable logistic regression
model, both markers were found to be independent predic-
tors. Compared to patients with no ST2, there was a trend
towards a higher six-month death/(re)MI rate among pa-
tients with 1 mm ST2 (OR 1.34; 95% CI: 0.86, 2.09); and
a significant increase in the rate among patients with ST2
2 mm (OR 1.91; 95% CI: 1.10, 3.32). Patients with cTnT
levels higher than 0.278 ng/ml had approximately four times
the likelihood of an adverse event compared with patients
with no cTnT elevation (OR 3.86; 95% CI: 2.24, 6.66).
Our study has several interesting secondary findings.
First, our results underscore the prognostic importance of
lower levels of cTnT. The PARAGON-B troponin T
substudy defined positivity as 0.1 ng/ml; however, in
examining the relationship between continuous cTnT and
six-month outcomes, we found this dichotomization may be
less than optimal for risk stratification. Patients with cTnT
levels in the range of 0.01 to 0.047 ng/ml had six-month
death/(re)MI rates of 14.2% compared with 6.3% among
patients with no detectable cTnT. Our results are consistent
with those reported recently by Lindhal et al. (6). In the
Fast Revascularization during Instability in Coronary artery
disease (FRISC-II) substudy, any detectable elevation of
cTnT was associated with higher risk of (re)MI or death at
one year. One limitation of using lower cTnT cutoffs is the
greater variability and loss in precision. Typical analytical
performance of the cTnT assay used in the current study is
characterized by a precision (CV) of about 20% at 0.01
ng/ml, the 99th percentile for a reference control population
(95% CI: 0.006 to 0.014). The precision (CV) at 0.03 ng/ml
achieves 10% (95% CI: 0.024 to 0.036); at cTnT concen-
trations 0.05 ng/ml the precision (CV) is constant at 5%
to 8% (data on file at Roche Diagnostics).
Second, the time from symptom onset to evaluation
appears to have a significant impact on the prognostic value
of the markers. Patients with ST2 2 mm after 6 h of
symptom onset had more than three times the risk of
six-month death/(re)MI compared with patients with ST2
2 mm on ECGs done within 6 h (OR 7.3 vs. 2.1). Worse
outcomes with persistent ST2 may be indicative of worse
myocardial ischemia and/or more extensive or severe coro-
nary artery disease. Given the potential prognostic implica-
tions, further exploration of the temporal evolution of
ST-segment changes is warranted.
In contrast, earlier elevations of cTnT appear to be
markers of higher risk. A possible explanation is that early
elevations of troponin are indicators of higher risk patients
with active lesions and “stuttering” courses of intermittent
occlusion and reperfusion preceding their ultimate presen-
tation for medical attention. This hypothesis is supported,
in part, by the higher frequency of cardiac symptoms among
these patients in the two weeks prior to study enrollment
(80% vs. 69%) (Table 7). Our results are consistent with
those from the Thrombolysis In Myocardial Infarction
(TIMI)-IIIb troponin I analysis in which patients enrolled
within 6 h of symptom onset who had elevated troponin I
levels had a 42-day mortality rate of 3.1% compared with
1.7% among patients without early troponin I elevations (3).
In our study, the corresponding 30-day mortality rates were
3.9% among cTnT-positive and 1.4% among cTnT-
negative patients. While the TIMI-IIIb result among pa-
tients presenting after 6 h of symptom onset appears
inconsistent with our findings (42-day mortality risk ratio of
9.5 between troponin I positive and negative patients), this
result is driven by the extremely low-risk of troponin I
negative patients (0.4% mortality compared with 4.0%
among troponin I positive patients). Among corresponding
patients in our study, 30-day mortality rate in cTnT-
positive patients was similar to those of the TIMI-IIIb
cohort (3.6%) but was much higher among cTnT-negative
patients (2.1%) resulting in a lower risk ratio.
Third, our study shows that cTnT is superior to ST2 in
assisting treatment decisions, especially in the short-term.
Among cTnT-positive patients, treatment with a GP IIb/
IIIa inhibitor (lamifiban) significantly reduced the risk of
both (re)MI (8.5 vs. 17.3, p  0.01) and the composite
outcome of death/(re)MI (11.1 vs. 18.8, p  0.04) in the
short term and of (re)MI alone at six months (9.1 vs. 18.0,
p  0.01). Although death/(re)MI rates were consistently
lower among patients treated with lamifiban compared with
placebo across all ST-depression categories, the differences
did not reach statistical significance. Therefore, while the
presence of ST-segment changes at baseline may have
important prognostic information with respect to coronary
revascularization (22,23), they may offer less guidance with
respect to pharmacotherapy.
Two issues associated with the current study must be
noted. First, an analysis examining the combined value of
baseline ECG and troponins with respect to response to
Table 6. Treatment Effect by Troponin Status
Characteristics cTnT  cTnT
Treatment Rx Placebo Rx Placebo
Sample size 290 288 190 191
Death 30 day 1.4 2.1 3.2 4.2
Death 6 month 2.8 3.8 8.0 6.9
MI 30 day 9.3 8.7 8.5 17.3*
MI 6 month 9.9 9.5 9.1 18.0*
Death/MI 30 day 9.7 9.4 11.1 18.8†
Death/MI 6 month 10.3 11.5 15.3 20.9
*Treatment groups are statistically significantly different at p 0.01 level; †treatment
group comparison p  0.04.
Abbreviations as in Table 1.
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treatment would be of interest; however, the small sample
sizes in some of the groups limit the utility of such an
analysis. Second, the cTnT and ST2 measures used in our
analysis were analyzed in core laboratories and, therefore,
were not available to investigators. However, the investiga-
tors had access to the ECGs and may have had access to
local cTnT data, which may have influenced decisions
regarding revascularization therapy. This in turn may have
had an impact on outcomes. A preliminary analysis revealed
no relationship between increasing ST2 and procedure use;
however, cTnT-positive patients had a higher frequency of
revascularization. We believe that these issues are beyond
the scope of the current investigation and deserve further
exploration.
Comparison with previous studies. Earlier studies exam-
ining the relative contributions of ST2 and cTnT positivity
have focussed on short-term prognosis. Holmvang et al.
(24) examined the combined value of ECG and biochemical
assessment for very early risk stratification among patients
with unstable coronary artery disease as part of the Throm-
bin Inhibition in Myocardial Ischemia (TRIM) substudy.
Among 470 patients with readable ECGs, 64 (14%) had
ST2 of at least 1 mm in any lead. In univariate analyses,
both ST2 and cTnT 0.1 ng/ml were highly predictive of
death/(re)MI within 30 days. Although in the multivariable
context, cTnT did not provide additional prognostic infor-
mation over and above that of ST2, it was effective in
further risk-stratifying patients with no ST2 (30-day
death/[re]MI rates of 6% and 3% among cTnT positive and
negative patients, respectively).
As part of the Fast Assessment of Thoracic Pain (FAST)
study, Jernberg et al. (25) examined the combination of a
continuous 12-lead ECG and cTnT status in patient
risk-stratification. As in our study, cTnT positivity was
defined as 0.10 ng/ml, however, ST2 was categorized
into 0.05 mV to 0.10 mV and 0.10 mV. In addition,
ST episodes defined as a transient ST2 or elevations in any
lead of at least 1 mm were identified. In a multivariable
model, cTnT and ST episodes were independent predictors
of 30-day death/(re)MI. Neither category of ST2 was
found to be a statistically significant predictor of outcomes.
CONCLUSIONS
Our study documents that quantitative ST2 and cTnT
status are complementary in assessing risk among ACS
patients and that both should be employed to determine
prognosis and assist in medical decision making. While
both ST2 and cTnT are effective markers of risk, cTnT
appears to be superior to ST2 in assisting decisions
regarding the use of GP IIb/IIIa therapy. Furthermore,
levels of cTnT lower than 0.1 ng/ml contain important
prognostic information and should be incorporated into
risk-assessment analysis. The relationship between cTnT
and ST2 status and outcomes over a spectrum of times
from symptom onset require further investigation.
Table 7. Examining the Impact of Time to ECG and Time to cTnT on Their
Prognostic Significance
ST2
Time From Onset of
Symptoms to ECG < 6 h
Time From Onset of
Symptoms to ECG > 6 h
Number of patients 743 144
Distribution of ST2
No ST2 281 (38%) 69 (48%)
1 mm ST2 344 (46%) 63 (44%)
ST2 2 mm 118 (16%) 12 (8%)
Association with outcomes
(OR for 6-Month death/MI)
1 mm ST2 1.2 (0.8–2.0) 4.2 (1.1–15.9)
ST2  2 mm 2.1 (1.2–3.7) 7.3 (1.3–42.0)
Duration of pain in min* 30 (20, 120) 210 (38, 618)
Troponin
Time From Onset of
Symptoms to Troponin < 6 h
Time From Onset of
Symptoms to Troponin > 6 h
Number of patients 421 532
Distribution of troponin values
Negative 294 (70%) 280 (53%)
Positive 127 (30%) 252 (47%)
Continuous troponin* 0.02 (0, 0.14) 0.09 (0, 0.42)
Association with outcomes
(OR for 6-month death/MI)
Positive 2.4 (1.4, 4.2) 1.5 (0.92–2.5)
Symptoms of MI/UA in the last
2 weeks
80% 69%
Duration of pain in min* 30 (20, 64) 60 (25, 210)
*Values presented are medians and interquartile range.
cTnT  cardiac troponin T; UA  unstable angina; other abbreviations as in Table 1.
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